Psychedelics company MindMed's shares slide 36% premarket as it prices dilutive 7.1 million share secondary offeringMarket Watch • 09/28/22
MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like SubstancesPRNewsWire • 09/20/22
MindMed Announces Positive Results from Collaborators' Placebo-Controlled Investigator-Initiated Trial Published in Peer-Reviewed JournalPRNewsWire • 09/08/22
Wall Street Analysts Predict a 399% Upside in Mind Medicine MindMed Inc. (MNMD): Here's What You Should KnowZacks Investment Research • 08/30/22
MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety DisorderPRNewsWire • 08/25/22